These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 38616443)
1. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know. Downs-Canner S; Weiss A Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443 [TBL] [Abstract][Full Text] [Related]
2. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784 [TBL] [Abstract][Full Text] [Related]
3. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293 [TBL] [Abstract][Full Text] [Related]
4. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Leon-Ferre RA; Hieken TJ; Boughey JC Ann Surg Oncol; 2021 Apr; 28(4):2111-2119. PubMed ID: 33486641 [TBL] [Abstract][Full Text] [Related]
5. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074 [TBL] [Abstract][Full Text] [Related]
6. Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy. Tasoulis MK; Muktar S; Smith I; Roche N; MacNeill F Eur J Surg Oncol; 2024 Jun; 50(6):108277. PubMed ID: 38522333 [TBL] [Abstract][Full Text] [Related]
7. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952 [TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers? Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647 [TBL] [Abstract][Full Text] [Related]
9. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer. Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care. Roberts A; Hallet J; Nguyen L; Coburn N; Wright FC; Gandhi S; Jerzak K; Eisen A; Look Hong NJ Breast Cancer Res Treat; 2024 Jul; 206(2):227-244. PubMed ID: 38676808 [TBL] [Abstract][Full Text] [Related]
11. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM; Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810 [TBL] [Abstract][Full Text] [Related]
12. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer. Harbeck N Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172 [TBL] [Abstract][Full Text] [Related]
13. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Harbeck N; Gluz O Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920 [TBL] [Abstract][Full Text] [Related]
16. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW; Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226 [TBL] [Abstract][Full Text] [Related]
17. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Taguchi T Breast Cancer; 2017 Jan; 24(1):63-68. PubMed ID: 26754092 [TBL] [Abstract][Full Text] [Related]
18. When and how do I use neoadjuvant chemotherapy for breast cancer? Rapoport BL; Demetriou GS; Moodley SD; Benn CA Curr Treat Options Oncol; 2014 Mar; 15(1):86-98. PubMed ID: 24306808 [TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586 [TBL] [Abstract][Full Text] [Related]
20. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Golshan M; Cirrincione CT; Sikov WM; Berry DA; Jasinski S; Weisberg TF; Somlo G; Hudis C; Winer E; Ollila DW; Ann Surg; 2015 Sep; 262(3):434-9; discussion 438-9. PubMed ID: 26222764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]